Сравнение
Ganirelix vs. Bremelanotide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
123246-29-7
189691-06-3
Молекулярная масса
1570.3 g/mol
1025.18 g/mol
Период полувыведения
нет данных
2.7 h
Последовательность
нет данных
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHМеханизм действия
Ganirelix
Ganirelix competitively and reversibly binds the pituitary GnRH receptor, rapidly suppressing LH (and, less so, FSH) release — without the initial hormone 'flare' of GnRH agonists.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
1
5
из них на людях
1
5
Зафиксированные эффекты
2
3
Открытые противоречия
0
1
Задокументированные нежелательные явления
1
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Ganirelix and Bremelanotide?
- Ganirelix is classified as "Исследования (прочее)", while Bremelanotide is classified as "Исследования (прочее)". Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Ganirelix or Bremelanotide?
- The highest available evidence level is "РКИ на людях" for Ganirelix and "РКИ на людях" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Ganirelix and Bremelanotide in Germany and the United States?
- Германия: Ganirelix — Рецептурный, Bremelanotide — Не одобрено. США: Ganirelix — Рецептурный, Bremelanotide — Рецептурный. These are factual summaries with source and review date on the individual pages.